WEBULL
WebtradeDownload

LeMaitre Vascular (LMAT) Faces A Leadership Transition, Is It Still Below Fair Value?

Simply Wall St · 2d ago

LeMaitre Vascular (LMAT) is in focus after President David B. Roberts notified the company on October 9 that he plans to retire from his executive role at the end of the year.

LeMaitre Vascular’s leadership update lands after a mixed period for investors, with the share price at US$83.16 and a 7 day share price return of 4.42% hinting at a short term rebound. Over longer periods, the 90 day share price return declined 18.17% and the 1 year total shareholder return slipped 3.27%, in contrast with a much stronger 3 year total shareholder return of 77.52% that reflects a very different longer run experience for holders.

Scan how LeMaitre Vascular compares with other medical and healthcare stocks that have recently caught investor attention using the curated 32 resilient stocks with low risk scores.

After a quick bounce and with LeMaitre Vascular trading below analyst price targets yet above some intrinsic estimates, investors are left weighing one issue: Is the caution around this retirement driven transition giving you an entry discount or a warning signal?

Most Popular Narrative: 22% Undervalued

At a last close of $83.16 against a fair value narrative of $107, LeMaitre Vascular is framed as trading at a sizeable discount, with that gap hinging on how well management turns pricing power, logistics projects and tissue capacity into sustained results.

The relocalization and direct to hospital logistics buildout, including new or enlarged warehouses in locations such as Billerica, Madrid, Paris, Toronto, Dublin and Warsaw, has already cut shipping costs in examples like Spain and is linked to multi point European gross margin expansion. This in turn suggests further margin and earnings benefit as these facilities mature and more countries move to direct distribution.

See why 6 investors see LeMaitre Vascular as 22% undervalued.

Result: Fair Value of $107 (UNDERVALUED)

Still, the LeMaitre Vascular story can change quickly if tissue supply and regulatory pressures deepen, or if further guidance cuts reset confidence in its pricing playbook.

Find out about the key risks to this LeMaitre Vascular narrative.

Another View: What Multiples Say About LeMaitre Vascular

That $107 fair value story leans on long term earnings forecasts. The P/E picture is less forgiving. LeMaitre Vascular trades on roughly 29x earnings, richer than the US Medical Equipment sector at 24.7x and above a fair ratio of 22.8x that the market could move toward. If sentiment cools on the growth narrative, how comfortable are you with paying this kind of premium?

To see how those valuation gaps line up with the current price, and what that might mean for risk or opportunity, See what the numbers say about this price — find out in our valuation breakdown..

NasdaqGM:LMAT P/E Ratio as at Oct 2026
NasdaqGM:LMAT P/E Ratio as at Oct 2026

Next Steps

There have been mixed messages in the LeMaitre Vascular story so far. If you want to move quickly and stress test the upside case, review the 2 key rewards.

Looking for more investment ideas beyond LeMaitre Vascular?

Do not stop at LeMaitre Vascular. Use the Simply Wall Street Screener to surface fresh opportunities that fit your style before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.